Mie University
12
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
13%
1 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease
Role: collaborator
Elucidate Vasodilatory Capacity From Histology-Defined Analysis of Coronary CT Angiography
Role: collaborator
Investigator Initiated Phase 1 Study of TBI-1201
Role: lead
Dynamic Stress Perfusion CT for Detection of Inducible Myocardial Ischemia
Role: collaborator
Carotid Artery Stenting With Cilostazol Addition for Restenosis
Role: collaborator
Neuroinflammation During ICU-associated Delirium in Critically Ill Patients and Its Association With Structural and Functional Brain Alterations: a Nested Case-control Study
Role: collaborator
Radiofrequency Ablation in Resectable Colorectal Lung Metastasis
Role: lead
Investigator Initiated Phase 1 Study of TBI-1301
Role: lead
Changes in Adrenal Hormones During Adrenal Radiofrequency Ablation
Role: lead
Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration
Role: lead
Predictive Factors of Ranibizumab Treatment in Macular Edema With CRVO
Role: lead
Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers
Role: collaborator
All 12 trials loaded